NZ706420A - Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors - Google Patents
Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factorsInfo
- Publication number
- NZ706420A NZ706420A NZ706420A NZ70642013A NZ706420A NZ 706420 A NZ706420 A NZ 706420A NZ 706420 A NZ706420 A NZ 706420A NZ 70642013 A NZ70642013 A NZ 70642013A NZ 706420 A NZ706420 A NZ 706420A
- Authority
- NZ
- New Zealand
- Prior art keywords
- inhibitor
- masitinib
- tyrosine kinase
- mast cell
- treatment
- Prior art date
Links
- 239000002139 L01XE22 - Masitinib Substances 0.000 title abstract 4
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 title abstract 4
- 229960004655 masitinib Drugs 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 5
- 229940124204 C-kit inhibitor Drugs 0.000 abstract 4
- 210000003630 histaminocyte Anatomy 0.000 abstract 4
- 239000003112 inhibitor Substances 0.000 abstract 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 4
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 abstract 4
- 229940034982 antineoplastic agent Drugs 0.000 abstract 3
- 239000002246 antineoplastic agent Substances 0.000 abstract 3
- 230000014509 gene expression Effects 0.000 abstract 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 1
- 229960005277 gemcitabine Drugs 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 210000004976 peripheral blood cell Anatomy 0.000 abstract 1
- 239000000092 prognostic biomarker Substances 0.000 abstract 1
- 230000004797 therapeutic response Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12306214 | 2012-10-04 | ||
| PCT/EP2013/070741 WO2014053650A1 (en) | 2012-10-04 | 2013-10-04 | Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ706420A true NZ706420A (en) | 2018-08-31 |
Family
ID=47073382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ706420A NZ706420A (en) | 2012-10-04 | 2013-10-04 | Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10238649B2 (enExample) |
| EP (1) | EP2903616B8 (enExample) |
| JP (1) | JP6234466B2 (enExample) |
| KR (1) | KR102149483B1 (enExample) |
| CN (1) | CN104968347A (enExample) |
| AR (1) | AR092899A1 (enExample) |
| AU (1) | AU2013326463B2 (enExample) |
| BR (1) | BR112015007144A2 (enExample) |
| CA (1) | CA2886979C (enExample) |
| DK (1) | DK2903616T3 (enExample) |
| EA (1) | EA037368B1 (enExample) |
| ES (1) | ES2656640T3 (enExample) |
| IL (1) | IL238107B (enExample) |
| MX (1) | MX369999B (enExample) |
| NZ (1) | NZ706420A (enExample) |
| SG (1) | SG11201502626PA (enExample) |
| SI (1) | SI2903616T1 (enExample) |
| TW (1) | TWI609686B (enExample) |
| WO (1) | WO2014053650A1 (enExample) |
| ZA (1) | ZA201503054B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160244845A1 (en) * | 2013-10-04 | 2016-08-25 | Ab Science | Method for determining the prognosis of pancreatic cancer |
| MX2016014574A (es) * | 2014-05-08 | 2017-02-23 | Oncoethix Gmbh | El uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de mama triple-negativo. |
| TW201615222A (zh) * | 2014-10-24 | 2016-05-01 | 朗齊生物醫學股份有限公司 | 免疫疾病用藥臨床新應用 |
| EP3280448B1 (en) | 2015-04-10 | 2020-12-30 | Capsugel Belgium NV | Abiraterone acetate lipid formulations |
| RS62108B1 (sr) | 2016-03-02 | 2021-08-31 | Eisai R&D Man Co Ltd | Antitelo-lek konjugati na bazi eribulina i postupci primene |
| NZ745778A (en) * | 2016-03-25 | 2022-07-01 | Ab Science | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation |
| CN107267454B (zh) * | 2016-04-07 | 2025-05-23 | 内蒙古原生元生物科技有限公司 | 一种脐血nk细胞的体外扩增方法及其试剂盒与应用 |
| AU2018209164B2 (en) | 2017-01-17 | 2021-11-04 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CN110381938A (zh) * | 2017-02-01 | 2019-10-25 | 大连万春布林医药有限公司 | 减少中性粒细胞缺乏症的方法 |
| CN118903436A (zh) | 2018-01-31 | 2024-11-08 | 德西费拉制药有限责任公司 | 治疗肥大细胞增多症的组合疗法 |
| US20210398672A1 (en) * | 2018-10-29 | 2021-12-23 | Northwestern University | Big Data-Driven Personalized Management of Chronic Pain |
| WO2020115108A1 (en) * | 2018-12-06 | 2020-06-11 | Sørlandet Sykehus Hf | Egfr inhibitors and their use in the treatment of neuroathic pain |
| WO2020115261A1 (en) * | 2018-12-07 | 2020-06-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| NZ784949A (en) | 2019-08-12 | 2025-09-26 | Deciphera Pharmaceuticals Llc | Ripretinib for treating gastrointestinal stromal tumors |
| SMT202400484T1 (it) | 2019-12-30 | 2025-01-14 | Deciphera Pharmaceuticals Llc | Composizioni di 1-(4-bromo-5-(1-etil-7-(metilammino)-2-osso-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofenil)-3-fenilurea |
| CN114214396A (zh) * | 2020-06-30 | 2022-03-22 | 宁波市康宁医院(宁波市精神疾病预防控制中心、宁波市微循环与莨菪类药研究所) | Gabrd甲基化作为抗海洛因复吸靶点的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8450302B2 (en) * | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| MXPA05001277A (es) | 2002-08-02 | 2005-10-06 | Ab Science | 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit. |
| WO2007015935A2 (en) | 2005-07-29 | 2007-02-08 | Bayer Healthcare Llc | Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy |
| US20100143935A1 (en) | 2006-12-01 | 2010-06-10 | Apocell, Inc. | c-KIT Phosphorylation in Cancer |
| JP2010515708A (ja) | 2007-01-12 | 2010-05-13 | アブ サイエンス | 代謝拮抗薬およびチロシンキナーゼ阻害剤を用いた固形癌の併用治療 |
| SI2118099T1 (sl) | 2007-02-13 | 2011-11-30 | Ab Science | Postopek za sintezo 2-aminotiazolnih spojin kot kinaznih inhibitorjev |
| WO2011056963A1 (en) | 2009-11-04 | 2011-05-12 | The University Of North Carolina At Chapel Hill | Methods and compositions for predicting survival in subjects with cancer |
| AR080096A1 (es) | 2010-02-01 | 2012-03-14 | Ab Science | Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib |
| WO2012170640A1 (en) * | 2011-06-07 | 2012-12-13 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for trail-drug combination therapy |
-
2013
- 2013-10-04 AU AU2013326463A patent/AU2013326463B2/en not_active Ceased
- 2013-10-04 WO PCT/EP2013/070741 patent/WO2014053650A1/en not_active Ceased
- 2013-10-04 BR BR112015007144A patent/BR112015007144A2/pt not_active Application Discontinuation
- 2013-10-04 MX MX2015004264A patent/MX369999B/es active IP Right Grant
- 2013-10-04 KR KR1020157011764A patent/KR102149483B1/ko active Active
- 2013-10-04 CA CA2886979A patent/CA2886979C/en active Active
- 2013-10-04 SG SG11201502626PA patent/SG11201502626PA/en unknown
- 2013-10-04 SI SI201330891T patent/SI2903616T1/en unknown
- 2013-10-04 EP EP13773731.8A patent/EP2903616B8/en active Active
- 2013-10-04 NZ NZ706420A patent/NZ706420A/en not_active IP Right Cessation
- 2013-10-04 EA EA201500373A patent/EA037368B1/ru unknown
- 2013-10-04 ES ES13773731.8T patent/ES2656640T3/es active Active
- 2013-10-04 AR ARP130103596A patent/AR092899A1/es unknown
- 2013-10-04 TW TW102136110A patent/TWI609686B/zh not_active IP Right Cessation
- 2013-10-04 US US14/433,198 patent/US10238649B2/en active Active
- 2013-10-04 DK DK13773731.8T patent/DK2903616T3/da active
- 2013-10-04 CN CN201380063241.4A patent/CN104968347A/zh active Pending
- 2013-10-04 JP JP2015535036A patent/JP6234466B2/ja active Active
-
2015
- 2015-04-01 IL IL238107A patent/IL238107B/en active IP Right Grant
- 2015-04-08 ZA ZA2015/03054A patent/ZA201503054B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2886979C (en) | 2021-01-05 |
| JP6234466B2 (ja) | 2017-11-22 |
| TW201414475A (zh) | 2014-04-16 |
| MX2015004264A (es) | 2015-10-12 |
| EP2903616A1 (en) | 2015-08-12 |
| WO2014053650A1 (en) | 2014-04-10 |
| KR20150092739A (ko) | 2015-08-13 |
| CN104968347A (zh) | 2015-10-07 |
| EP2903616B8 (en) | 2018-02-07 |
| SG11201502626PA (en) | 2015-05-28 |
| JP2015532296A (ja) | 2015-11-09 |
| US20150272945A1 (en) | 2015-10-01 |
| AU2013326463B2 (en) | 2018-01-18 |
| EA201500373A1 (ru) | 2016-02-29 |
| EA037368B1 (ru) | 2021-03-19 |
| EP2903616B1 (en) | 2017-12-13 |
| AR092899A1 (es) | 2015-05-06 |
| US10238649B2 (en) | 2019-03-26 |
| ES2656640T3 (es) | 2018-02-27 |
| CA2886979A1 (en) | 2014-04-10 |
| BR112015007144A2 (pt) | 2017-12-12 |
| TWI609686B (zh) | 2018-01-01 |
| MX369999B (es) | 2019-11-28 |
| IL238107B (en) | 2018-03-29 |
| AU2013326463A1 (en) | 2015-04-16 |
| ZA201503054B (en) | 2016-11-30 |
| DK2903616T3 (da) | 2018-01-29 |
| SI2903616T1 (en) | 2018-02-28 |
| KR102149483B1 (ko) | 2020-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ706420A (en) | Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors | |
| IN2014DN09678A (enExample) | ||
| WO2012006589A3 (en) | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling | |
| MX368513B (es) | Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón. | |
| EA201491584A1 (ru) | Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor | |
| MX2015010372A (es) | Objetivo terapeutico y de diagnostico para el cancer que comprende reactivos que se unen con dll3. | |
| WO2014205555A8 (en) | Methods and uses for diagnosis and treatment of prostate cancer | |
| MX2021010672A (es) | Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer. | |
| MX2011007397A (es) | Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos. | |
| MX2014016014A (es) | Metodos para determinar eficacia de farmacos usando proteinas asociadas a cereblon. | |
| BR112018074981A2 (pt) | tratamentos de câncer | |
| EA201290138A1 (ru) | Производные пиразола как модуляторы кальциевых каналов, активируемых высвобождением кальция | |
| MX365421B (es) | Método in-vitro para diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-maf. | |
| EP2114990A4 (en) | EXPRESSION PROFILES OF GENES AND PROTEINS ASSOCIATED WITH THE THERAPEUTIC EFFICACY OF EGFR-TK INHIBITORS | |
| BRPI0907637A8 (pt) | biomarcadores p53 | |
| WO2018183817A3 (en) | Tumor burden as measured by cell free dna | |
| MX2014014097A (es) | Biomarcadores para determinar la respuesta eficaz de tratamientos en pacientes de carcinoma hepatocelular (chc). | |
| EA201591522A1 (ru) | Лечение реакции трансплантат против хозяина у подвергаемых трансплантации пациентов | |
| CY1117234T1 (el) | Μεθοδος προσδιορισμου της ευαισθησιας ασθενους στη θεραπεια αναστολης της τελομερασης | |
| GB2523211A (en) | MCT protein inhibitor-related prognostic and therapeutic methods | |
| EA201490201A1 (ru) | Выявление экспрессии гена prame при раковом заболевании | |
| DE602006011959D1 (de) | Na+, k+-atpase-expression bei zervixdysplasie und -krebs | |
| WO2013188823A3 (en) | Cancer prognostic assays | |
| Wu et al. | Changes of folate receptor-α protein expression in human gliomas and its clinical relevance | |
| BR112014019034A8 (pt) | Método para tratamento de câncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 OCT 2020 BY DENNEMEYER + CO. Effective date: 20190923 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 OCT 2021 BY DENNEMEYER + CO. S.A.R.L. Effective date: 20200921 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 OCT 2022 BY DENNEMEYER + CO. Effective date: 20210928 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 OCT 2023 BY DENNEMEYER + CO. S.A.R.L. Effective date: 20220926 |
|
| LAPS | Patent lapsed |